Transforming Lives
Innovation, fueled by science and a passion for patients
PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our promise to create more moments for those who count on us.
Focused research platforms at work for patients
Challenging what's possible
Harnessing groundbreaking science for patients has led to many firsts – the first approved treatment for Duchenne in the world, the first approved gene therapy directly infused into the brain, and the first approved small molecule splicing modifier. Our innovative pipeline continues to expand as we discover and develop treatments using the newest technologies available.
Clinical Trials
We are committed to making progress in rare disease through clinical trial research.
We love what we do
PTC employees are working to change patients’ lives every single day.
We are motivated by our patients and the drive for them to have more moments with their families, made possible in part by our research and therapies.
If you’re looking to take on rewarding work with inspiring colleagues, come grow with us.
Making headlines
-
NEWSROOM
PTC UK: The Passion that Keeps Us Going
PTC UK was the first office to open in Europe and hire the first employees to serve our patients in the region. Today, 23 employees are based in the UK, leading regional and global functions. -
NEWSROOM
Investing in Employees’ Learning and Development
At PTC, we invest in our people and dedicate resources to development and learning, ensuring our employees are supported and empowered in their careers. -
PRESS RELEASE
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
PTC Therapeutics shared interim results from the Phase 2 PIVOT-HD study of PTC518 in Huntington's disease (HD) patients.